Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →
Indian pharma companies disburse ₹4-12 lakh per MR per year across fixed salary, variable per-doctor incentive, sample distribution at landed cost, travel and DA, and CME support — with Section 17(2)(vi) perquisite exposure on unaccounted samples, UCPMP 2024 sample and gifting caps, CSR-vs-marketing expense classification, and Section 393 code 1002 TDS on contractor MR engagements all overlapping on the same expense ledger.
Reconcile MR-wise sample issuance against doctor-acknowledged consumption with the unaccounted balance pushed into Section 17(2)(vi) perquisite at year end, variable incentive computed against per-doctor coverage achievement and reconciled to field activity logs, expense claim approved against territory norms and CSR-coded entries segregated from marketing-coded entries, and contractor MR payments TDS-deducted under Section 393(1)(a) code 1002 with PAN-aggregated annual thresholds tracked.
MR master keyed by employee or contractor flag, territory tier and therapeutic area; doctor master with registration number and UCPMP interaction history; sample ledger with batch and expiry tracking per MR; expense norm matrix by territory; per-doctor coverage and incentive band table; CSR-vs-marketing expense classifier rules; Section 393(1)(a) code 1002 vendor rate matrix for contractor MR agencies; Section 192 code 1001 payroll perquisite line for unaccounted samples.
A monthly reconciled view per MR showing salary plus variable plus expense plus sample distribution totals against the budget band, an unaccounted-sample exposure pushed to payroll as Section 17(2)(vi) perquisite, UCPMP breach flags per doctor where sample or hospitality caps are exceeded, CSR-vs-marketing expense allocation per cost centre, and the monthly TDS challan tied to Section 393 code 1002 on contractor MR agency payments.
A mid-sized Indian pharma company closes April books and pulls the field-force ledger: 280 medical representatives, ₹84 crore annual all-in cost, sample distribution at landed cost running ₹3.4 crore for the year, and a sample-ledger close showing ₹38 lakh of issued samples without doctor acknowledgement slips. The numbers are predictable for any medical representative settlement India operation that runs MR cost on spreadsheets and a payroll system that doesn’t talk to the sample register. The full stack covers five distinct rails and a tax overlay that interacts with each one.
Quick reference
| Item | Value |
|---|---|
| Typical per-MR annual cost band | ₹4-12 lakh all-in (salary + variable + samples + travel + CME) |
| Sample distribution tax treatment | Section 17(2)(vi) perquisite on unaccounted samples |
| Marketing code regulator | DoP (Department of Pharmaceuticals) under UCPMP 2024 with CDSCO coordination |
| UCPMP 2024 statutory basis | Issued under DPCO; mandatory self-certification for pharma companies |
| Key TDS codes | 1001 (Section 192 salary — payroll MR), 1002 (Section 393(1)(a) contractor — agency MR) |
| Variable incentive band | Typically 10-15% of CTC tied to per-doctor coverage achievement |
| Doctor master anchor | NMC registration number per HCP |
The MR cost stack
A field MR sits at the centre of five overlapping cost flows: a fixed monthly salary processed through payroll; a variable per-doctor incentive computed against coverage and prescription pull-through; an expense claim covering travel, daily allowance, local conveyance and entertainment under UCPMP-permissible heads; physician samples drawn from the dispatch warehouse and expected to be distributed to registered medical practitioners; and conference, CME and educational-material support classified separately from gifting. Each flow has its own approval workflow, its own taxonomy of variance, and its own intersection with the tax overlay.
Typical commercial pattern at a 280-MR pharma company with ₹84 crore annual MR cost: CTC band ₹3.6-7.2 lakh per MR, variable ₹40,000-1.6 lakh, travel and DA ₹60,000-1.5 lakh, sample distribution at landed cost ₹40,000-1 lakh, CME and educational support ₹20,000-50,000, and IT and connectivity ₹15,000-25,000 per MR per year.
The five reconciliation rails
Rail 1 — Salary and payroll reconciliation
The fixed component is the cleanest rail: gross CTC, statutory deductions (PF, ESI where applicable, professional tax), Section 192 TDS, and net credit to the MR’s bank account. The complication arrives at year end when the unaccounted-sample value (see Rail 3) lands as a Section 17(2)(vi) perquisite line on Form 16. The payroll reconciliation must accept a perquisite feed from the sample register, recompute TDS on salary under Section 192 (continuing as code 1001 under the new Income Tax Act 2025), and issue corrected Form 16 before the financial year close. Pharma companies that delay this run into 26AS mismatches between MR Form 16 and Form 26AS that the MR’s own income tax return triggers.
Rail 2 — Variable per-doctor incentive
Variable pay is computed against per-doctor coverage achievement: the MR’s target doctor list, the actual coverage frequency (in-person calls, sample drops, CME invitations), and prescription pull-through measured against a secondary-sales proxy from the stockist. Reconciliation must tie the per-doctor coverage log to the MR’s expense claim trail (a doctor visit with no travel claim or no sample drop is suspicious) and to the incentive band the MR is paid against. Typical variance modes: doctors who appear in coverage logs but never in stockist secondary sales; expense claims that exceed territory norms; and incentive calculations that overstate coverage because the doctor master is stale.
Rail 3 — Sample distribution and Section 17(2)(vi) perquisite
Physician samples leave the warehouse against an MR-wise requisition, get logged out to the MR at issuance with batch and expiry, and are expected to be distributed to registered medical practitioners against an acknowledgement slip carrying the doctor’s NMC registration number, clinic stamp and signature. The sample ledger close per MR per quarter produces three buckets: distributed-and-acknowledged, expired-and-returned-to-warehouse, and unaccounted. The unaccounted bucket is the problem — it is deemed consumed by the MR personally and is added to the MR’s Form 16 as a Section 17(2)(vi) perquisite at fair value, taxable in the MR’s hands. A ₹38 lakh unaccounted-sample close at a 280-MR company implies an average per-MR perquisite of ₹13,500 — material when stacked on variable pay and CTC.
See Pharma expiry returns: saleable vs non-saleable in India for the related warehouse-side expiry classification that interacts with sample-return ledger.
Rail 4 — Expense claim and UCPMP 2024 compliance
UCPMP 2024 — the Uniform Code for Pharmaceutical Marketing Practices, made statutory under DPCO and overseen by the Department of Pharmaceuticals with CDSCO coordination — prohibits cash and cash-equivalent gifts to healthcare professionals, restricts hospitality to genuine CME contexts, caps free physician samples per doctor per product per year, and requires pharma companies to maintain an auditable register of all interactions. Reconciliation must classify every MR expense claim against the UCPMP taxonomy: permissible CME support, permissible educational material, permissible sample distribution within the cap, and prohibited gifts or hospitality. A separate CSR-vs-marketing classifier runs on top — health-camp sponsorship that flows from a CSR cost centre cannot also flow as a marketing expense, and any expense that crosses the boundary triggers both a Section 37(1) disallowance (expenses incurred for any purpose which is an offence or prohibited by law are not deductible) and a CSR-utilisation audit issue.
[Inline calculator CTA goes here.]
How much is unmatched MR expense and sample exposure costing you?
Plug your MR headcount, sample distribution value and three-way exception rate into the calculator to size annual leakage and the Section 17(2)(vi) perquisite exposure.
Open the exception cost calculator →Rail 5 — Contractor MR and the Section 393 code 1002 overlay
Most pharma MRs are direct employees on payroll, with Section 192 (code 1001) salary TDS. A material minority sit on contractor terms — either engaged directly on a service agreement or routed through a third-party field-force agency. Contractor payments fall under Section 393(1)(a) of the new Income Tax Act 2025, payment code 1002 (which replaced legacy Section 194C). Rate is 1% for individual/HUF vendors and 2% for company/firm vendors, with thresholds of ₹30,000 per transaction and ₹1 lakh aggregate per year. The classification has consequences beyond TDS: UCPMP responsibility, Section 17(2) perquisite exposure, PF/ESI obligations, and the company’s gratuity actuarial all change depending on whether the MR is an employee or a contractor.
For the full code map under the new Act see TDS payment codes 1001-1092 India and the cross-era guidance in Section 393 TDS new Income Tax Act reconciliation.
Cross-era note: invoices and 26AS data raised under the previous Act (before 1 April 2026) will continue to carry legacy section references (192 for code 1001, 194C for code 1002) — reconciliation against historical Form 26AS data must keep the legacy section cross-reference live for at least one full tax-year cycle.
Worked example — pharma company with 280 MRs and ₹84 crore annual MR cost
A mid-sized pharma company, 280 MRs across 12 states, three therapeutic areas, ₹84 crore annual MR all-in cost (average ₹30 lakh per MR is high relative to the band — this build assumes a senior-skewed urban-tier force):
- Fixed CTC pool: ₹14.4 crore (₹30,000-60,000 monthly average)
- Variable incentive pool: ₹6.8 crore (8-15% of CTC, tied to per-doctor coverage)
- Travel and DA pool: ₹4.2 crore
- Sample distribution at landed cost: ₹3.4 crore annual; sample-ledger close shows ₹38 lakh unaccounted — pushed to payroll as Section 17(2)(vi) perquisite per MR
- CME and educational support pool: ₹1.4 crore — UCPMP-classified into compliant categories
- IT, connectivity and tablets: ₹0.6 crore
- Contractor MR agency spend: ₹54 crore against a 280-MR core plus a contractor field-force routed through two agencies; monthly Section 393(1)(a) code 1002 TDS challan ₹4.5-9 lakh
- Total: ₹84 crore against board-approved field-force budget; quarterly variance band ±3%
The structured close ties every line to a reason code: salary-paid, variable-earned, travel-approved, sample-acknowledged, sample-unaccounted-to-perquisite, CME-UCPMP-compliant, gift-UCPMP-breach, CSR-coded-spend, contractor-TDS-deducted. Without it, the close is a 12-15 day spreadsheet exercise across HR, finance and compliance; with it, the quarterly close runs inside four working days and the Section 17(2)(vi) perquisite feed into payroll lands clean.
CDSCO and UCPMP 2024 compliance framework
The Central Drugs Standard Control Organization (CDSCO) coordinates with the Department of Pharmaceuticals on UCPMP 2024 enforcement and maintains the regulatory anchor for pharma marketing-code compliance. For the current framework see the Central Drugs Standard Control Organization (CDSCO). Reconciliation systems at pharma companies typically encode the UCPMP taxonomy into the expense-claim classifier so that per-doctor sample caps, hospitality limits and gift prohibitions feed into the approval workflow automatically — UCPMP breaches surface at expense approval, not at the year-end self-certification.
What automated reconciliation changes
Manual MR settlement reconciliation across the five rails plus the tax overlay is a 12-15 day quarter-end exercise at a multi-state pharma company, and Rail-3 sample-ledger close routinely misses the cut-off for the Section 17(2)(vi) perquisite feed into Form 16. Purpose-built reconciliation software India treats each rail as a structured variance stream and surfaces only the lines that fail to match. TransactIG carries 24+ industry presets, including a configuration that handles MR salary plus variable plus expense reconciliation, sample-ledger close with unaccounted-sample perquisite push to payroll, UCPMP 2024 expense classification, CSR-vs-marketing segregation, and the Section 192 / Section 393 code 1001/1002 deduction map. Customer outcomes include match-rate improvement from 51% to 88%, and expense-claim exception rates moving into the sub-15% band post-implementation. Pair with GST reconciliation software for the GSTR-2B side of sample-warehouse and CME-vendor input credits. Build is two-to-four weeks on AWS Mumbai (ISO 27001:2022).